Name | 2-[(2R)-1-ethylsulfonyl-2-hydroxypropan-2-yl]-6-(trifluoromethyl)-1H-indole-5-carbonitrile |
---|---|
Synonyms | unii-3397afw49k |
Description | JNJ-26146900 is a potent and orally active androgen receptor antagonist with a Ki value of 400nM for rat AR. JNJ-26146900 is a nonsteroidal androgen receptor (AR) ligand. JNJ-26146900 reduces prostate tumor size and prevents bone loss. JNJ-26146900 can be used in research of cancer[1]. |
---|---|
Related Catalog | |
In Vitro | JNJ-26146900 与转染到 Cos-7 细胞中的大鼠雄激素受体结合,具有亚微摩尔效力[1]。 |
In Vivo | JNJ-26146900 (10-100 mg/kg; p.o.; 成年雄性 Sprague-Dawley 大鼠) 同样有效地降低腹侧前列腺和肛提肌肌肉的湿重[1]。 JNJ-26146900 (30-100 mg/kg; p.o.) 在 Dunning 大鼠模型中防止前列腺肿瘤生长,在 10mg/kg 的剂量下最大限度地抑制生长。 JNJ-26146900 在 CWR22-LD1 小鼠人前列腺癌异种移植模型中显着抑制肿瘤生长[1]。 JNJ-26146900 (30 mg/kg; p.o.; 成年雄性 Sprague-Dawley 大鼠) 减少去势诱导的胫骨骨质流失[1]。 Animal Model: mature male Sprague-Dawley rats[1] Dosage: 10, 30, 100 mg/kg Administration: oral gavage; daily, for 6 weeks Result: Reduced ventral prostate weight. Animal Model: CWR22-LD1 mouse xenograft model[1] Dosage: 30, 100 mg/kg Administration: oral gavage; twice per day for 3 weeks Result: Inhibited tumor growth at 100 mg/kg, reducing mean tumor weight at Day 21 to about 30% of the intact vehicle tumor weight. |
References |
Molecular Formula | C15H15F3N2O3S |
---|---|
Molecular Weight | 360.35 |
Exact Mass | 360.07600 |
PSA | 102.33000 |
LogP | 3.78138 |